AGIO
AGIOS PHARMACEUTICALS, INC.
Key Financials
Revenue
$54.0M
↑ 48.0%
Net Income
$-412781000
↓ 161.3%
Operating Income
$-472132000
↓ 10.9%
EPS (Diluted)
$-7.12
↓ 161.2%
Total Assets
$1.3B
↓ 22.0%
Shareholders' Equity
$1.2B
↓ 22.6%
Cash & Equivalents
$89.1M
↑ 16.9%
Operating Cash Flow
$-372977000.00
↑ 4.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 144 | 7/1/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AGIO |
| Company Name | AGIOS PHARMACEUTICALS, INC. |
| CIK | 1439222 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-649-8600 |